Sequential serum galactomannan as outcome marker for invasive aspergillosis: an exploratory study from the FungiScope registry
Background - Galactomannan index (GMI) is established as a diagnostic tool for invasive aspergillosis (IA), while its utility in monitoring antifungal treatment (AFT) response and prognostic value remains unclear. This study evaluated the validity of serum GM as a biomarker for AFT monitoring and it...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Article (Journal) |
| Lenguaje: | inglés |
| Publicado: |
February 2026
|
| In: |
International journal of infectious diseases
Year: 2026, Volumen: 163, Pages: 1-7 |
| ISSN: | 1878-3511 |
| DOI: | 10.1016/j.ijid.2025.108272 |
| Acceso en línea: | Resolving-System, kostenfrei, Volltext: https://doi.org/10.1016/j.ijid.2025.108272 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S1201971225004941 
|
| Notas de Autor: | Christina Többen, Oliver A. Cornely, Carolin S. Joisten, Ertan Sal, José A. Cozzi, Baptiste Hoellinger, Deniz Yilmaz Karapinar, Daniel Richter, Andreas H. Groll, Gustavo-Adolfo Méndez, Jeffrey D. Jenks, Nurettin Erben, Leyre López Soria, Philipp Koehler, Anna Apostolopoulou, Dries Deeren, Rika Draenert, Iker Falces-Romero, Julio Maquera-Afaray, Lisa Meintker, Ruwanthi Kolamunnage-Dona, Danila Seidel, Jannik Stemler |
| Sumario: | Background - Galactomannan index (GMI) is established as a diagnostic tool for invasive aspergillosis (IA), while its utility in monitoring antifungal treatment (AFT) response and prognostic value remains unclear. This study evaluated the validity of serum GM as a biomarker for AFT monitoring and its prognostic significance by correlating GMI with clinical response and survival of IA. - Objectives - Patients with IA and at least two sequential serum GMI measurements were identified from the FungiScope registry. Joint models of event-time and longitudinal outcome were used for imputing missing GMI to account for the relationship between GMI and time to death, as well as GMI and time to drop-out for the survival analysis and AFT response analysis, respectively. Cox proportional hazards models and logistic regression models assessed survival and clinical response on GMI changes at day 7, with baseline log GMI as an adjustment covariate. - Results - Among 66 patients with IA, correlation between day 7 GMI predictions and observed values was 92% and 88% in the survival and AFT analysis, respectively. GMI decreased in both patients who died within 42 days and those who survived, but maintained higher in patients who died. GMI increased or declined less in patients who died within 42 days, whereas in survivors, a continuous decline of GMI was observed. Patients with a baseline GMI < 1 had a higher survival rate until day 42 (17/21, 81.0%) compared to those with GMI ≥ 1 (31/45, 68.9%), with a risk of death twice as high as with GMI < 1 (HR = 2.107, P = 0.19). - Conclusion - Serum GMI is a non-invasive, predictive tool for estimating survival probability at onset of IA. Early GMI changes correlate with survival and could prompt timely AFT adjustment, potentially improving clinical outcomes. Additionally, GMI could serve as surrogate endpoint in clinical trials, facilitating development of new antifungal strategies. |
|---|---|
| Notas: | Online verfügbar: 10. Dezember 2025, Artikelversion: 02. Januar 2026 Gesehen am 19.05.2026 |
| Descripción Física: | Online Resource |
| ISSN: | 1878-3511 |
| DOI: | 10.1016/j.ijid.2025.108272 |